2026 Annual Meeting | Industry Therapeutic Update from Octapharma: Treating Autoimmune Diseases with Immunoglobulin Therapy: When Data Supports Practice

Date Monday 04/20/26

Time 06:00 PM - 08:00 PM CDT Add To Calendar

Location Marriott Marquis Chicago | Grand Horizon EFG

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Doors open at 5:30 pm CDT. Dinner will be provided.

Immune-mediated disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP) and dermatomyositis present ongoing challenges in diagnosis, treatment selection, and long-term management. As evidence continues to evolve, clinicians are increasingly asked to translate clinical trial data and real-world experience into practical treatment decisions.

In this Industry Therapeutic Update from Octapharma, expert faculty will review current clinical evidence supporting the use of immunoglobulin therapy in autoimmune and neuromuscular diseases and discuss how these data inform everyday practice.

The session will include:

1) Navigating the Complexity of CIDP Therapeutic Options
Jonathan S. Katz (Sutter Health, CA)

2) Exploring the Mechanisms of Action of IVIG in Autoimmune and Neuromuscular Diseases
Todd Levine (Bob Bove Neuroscience Institute at Honorhealth, AZ)

3) Changing Perspectives on Dermatomyositis: Key Insights from a Dermatologist
Gabriela Cobos (Tufts Medical Center, MA)

Presentations will feature data from recent clinical studies and illustrative patient cases involving CIDP or dermatomyositis. These insights will serve as a foundation for engaging discussions with the audience and support informed treatment decisions in daily clinical practice.
--------------------------------------

Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the �鶹��ýӳ��. These programs are not an official part of the 2026 �鶹��ýӳ�� Annual Meeting education or scientific programs, nor are they endorsed by the �鶹��ýӳ��. The �鶹��ýӳ�� cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 08:00 PM CDT	Speaker	Industry Therapeutic Update from Octapharma: Treating Autoimmune Diseases with Immunoglobulin Therapy: When Data Supports Practice

Faculty Disclosures
Todd D. Levine, MD	Dr. Levine has received personal compensation for serving as an employee of CND life sciences . Dr. Levine has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nufactor. Dr. Levine has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for PNA. Dr. Levine has or had stock in CND Life Sciences.Dr. Levine has or had stock in Corinthian reference lab.
Jonathan S. Katz, MD	Dr. Katz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Griffols. Dr. Katz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Katz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dianthus. Dr. Katz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Katz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kedrion. Dr. Katz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Katz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Griffols.